AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12468113 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure and heart rate measurements
Number of subjects: 20
Study 10199532 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased minute ventilation (VE) by +35%
Number of subjects: 20
Study 10199532 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced minute ventilation (VE) by -35%
Number of subjects: 20
Study 7775727 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 g psyllium fiber daily for 1 month
Number of subjects: 10
Study 7775727 — intervention group
Group type: COMPARATOR
Intervention: Placebo fiber daily for 1 month
Number of subjects: 10
Study 2187266 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 400867 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamimetic drug administered to the mother from week 33 to 35
Number of subjects: 0
Study 400867 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31645291 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based interventions for dengue prevention
Number of subjects: 983
Study 31645291 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach activities (video/debate sessions, school and home education sessions, focus groups)
Number of subjects: 983
Study 31645291 — intervention group
Group type: EXPERIMENTAL
Intervention: Community working groups for identifying and eliminating mosquito breeding sites
Number of subjects: 983
Study 31645291 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive text messages to residents
Number of subjects: 983
Study 28916479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate (NO3‐) ingestion via beetroot juice containing 11.2 mmol of NO3‐
Number of subjects: 8
Study 28916479 — intervention group
Group type: COMPARATOR
Intervention: Control group (beetroot juice devoid of NO3‐)
Number of subjects: 8
Study 27074186 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory Training (AT)
Number of subjects: 12
Study 27074186 — intervention group
Group type: COMPARATOR
Intervention: Visual Training (Control)
Number of subjects: 12
Study 25209523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozenoxacin 1% cream, applied twice daily for 4 days (every 12 h) with a single dose on day 1 and a final single dose on day 6.
Number of subjects: 46
Study 22310296 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 300
Study 22310296 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (early initiation within 48 hours)
Number of subjects: 300
Study 22310296 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (for influenza B)
Number of subjects: 300
Study 22310296 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 300
Study 20207062 — intervention group
Group type: EXPERIMENTAL
Intervention: IN ketorolac 31.5 mg
Number of subjects: 80
Study 20207062 — intervention group
Group type: COMPARATOR
Intervention: IN placebo
Number of subjects: 80
Study 17977171 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release dinoprostone vaginal insert (VI)
Number of subjects: 100
Study 17977171 — intervention group
Group type: COMPARATOR
Intervention: 0.5‐mg dinoprostone intracervical (IC) gel
Number of subjects: 100
Study 16411386 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived protein C zymogen concentrate (Ceprotin®, Baxter) (150 U/kg as a slow bolus infusion followed by 30 U/kg/h continuous infusion until 4 hours after LPS-infusion)
Number of subjects: 11
Study 16411386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 16411386 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived protein C zymogen concentrate (Ceprotin®, Baxter)
Number of subjects: 11
Study 12473152 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-educating transfusion request form
Number of subjects: 56171
Study 12473152 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 56171
Study 9824121 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics with constipation
Number of subjects: 0
Study 9824121 — intervention group
Group type: COMPARATOR
Intervention: Constipated controls
Number of subjects: 0
Study 9824121 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics
Number of subjects: 0
Study 9824121 — intervention group
Group type: COMPARATOR
Intervention: Community controls
Number of subjects: 0
Study 7657130 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (150 mg twice a day)
Number of subjects: 22
Study 7657130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2663681 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidin/naloxone (Valoron N; VAL)
Number of subjects: 0
Study 2663681 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (TRA)
Number of subjects: 0
Study 934534 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine (0.20 mg administered intravenously in standardized cycles of twenty administrations)
Number of subjects: 300
Study 30942385 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Music
Number of subjects: 45
Study 30942385 — intervention group
Group type: EXPERIMENTAL
Intervention: Melomics-Health Listening
Number of subjects: 45
Study 30942385 — intervention group
Group type: COMPARATOR
Intervention: No Music (Control)
Number of subjects: 45
Study 31192968 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional laser treatment
Number of subjects: 39
Study 31192968 — intervention group
Group type: COMPARATOR
Intervention: PASCAL treatment
Number of subjects: 39
Study 28202037 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multifaceted intervention over a 6 month trial period
Number of subjects: 300
Study 28202037 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study 28929698 — intervention group
Group type: EXPERIMENTAL
Intervention: S. flavescens gel (test group, 40 cases)
Number of subjects: 120
Study 28929698 — intervention group
Group type: COMPARATOR
Intervention: Human recombinant interferon α‐2b gel (control group, 40 cases)
Number of subjects: 120
Study 28929698 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of S. flavescens gel and human recombinant interferon α‐2b gel (combined application group, 40 cases)
Number of subjects: 120
Study 25163441 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g/kg alcohol (mean peak blood alcohol content of 0.051%)
Number of subjects: 24
Study 25163441 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol/energy drink
Number of subjects: 24
Study 25163441 — intervention group
Group type: COMPARATOR
Intervention: Energy drink alone (250 ml)
Number of subjects: 24
Study 23032549 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (200,000 IU initial dose, 200,000 IU one month later, then 100,000 IU monthly for 18 months)
Number of subjects: 322
Study 23032549 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical dosing regimen to vitamin D3)
Number of subjects: 322
Study 23032549 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 322
Study 23032549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 20656473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 169
Study 17557356 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic treatment (ON state)
Number of subjects: 73
Study 17557356 — intervention group
Group type: COMPARATOR
Intervention: Nonmedicated PD (OFF state)
Number of subjects: 73
Study 17557356 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants (Control)
Number of subjects: 73
Study 16787687 — intervention group
Group type: COMPARATOR
Intervention: docetaxel 75 mg/m2 plus cisplatin 75 mg/m2, every 3 weeks (DC)
Number of subjects: 926
Study 16787687 — intervention group
Group type: COMPARATOR
Intervention: docetaxel 75 mg/m2 and carboplatin 6 mg/ml min, every 3 weeks (DCb)
Number of subjects: 926
Study 16787687 — intervention group
Group type: EXPERIMENTAL
Intervention: vinorelbine 25 mg/m2/week plus cisplatin 100 mg/m2, every 4 weeks (VC)
Number of subjects: 926
Study 12066419 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphemic priming observed after identifying the colour of a single letter in the prime display.
Number of subjects: 0
Study 12066419 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic priming observed after identifying the colour of a single letter in the prime display.
Number of subjects: 0
Study 12066419 — intervention group
Group type: COMPARATOR
Intervention: Identifying the colour of a single letter in the Stroop task.
Number of subjects: 0
Study 10692755 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 26
Study 10692755 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg
Number of subjects: 26
Study 9127183 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient continence program
Number of subjects: 74
Study 9127183 — intervention group
Group type: COMPARATOR
Intervention: Inpatient continence program
Number of subjects: 74
Study 1863429 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ppm fluoride mouthrinse
Number of subjects: 0
Study 1863429 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 0
Study 6129458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 6129458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study 6129458 — intervention group
Group type: EXPERIMENTAL
Intervention: LM 24056
Number of subjects: 0
Study 6129458 — intervention group
Group type: EXPERIMENTAL
Intervention: Poldine
Number of subjects: 0
Study 29584516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia Training (IHT)
Number of subjects: 52
Study 29584516 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 28351962 — intervention group
Group type: EXPERIMENTAL
Intervention: Gly49 allele carriers
Number of subjects: 926
Study 28351962 — intervention group
Group type: COMPARATOR
Intervention: Ser49Ser genotype
Number of subjects: 926
Study 25982720 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation based on trial data
Number of subjects: 150264
Study 25982720 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related criteria
Number of subjects: 150264
Study 25982720 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior cardiac transplantation
Number of subjects: 150264
Study 25982720 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric electrophysiology operator
Number of subjects: 150264
Study 25982720 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade atrioventricular conduction disease
Number of subjects: 150264
Study 23336294 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg once daily started 6-8 hours after surgery)
Number of subjects: 12576
Study 23336294 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 12576
Study 23336294 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rivaroxaban and enoxaparin
Number of subjects: 12576
Study 21232874 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (0.1mg/kg body weight)
Number of subjects: 46
Study 21232874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 19597277 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-PTC
Number of subjects: 13
Study 19597277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 17023076 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit program (physical training plus information about their disease for 6 weeks)
Number of subjects: 137
Study 17023076 — intervention group
Group type: COMPARATOR
Intervention: Fit-Plus program (comprehensive cardiac rehabilitation including Fit program plus weekly psycho-education sessions and relaxation therapy for 8 weeks)
Number of subjects: 137
Study 15181655 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (administered for 8 weeks)
Number of subjects: 28
Study 15181655 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (maintained without change in daily dose)
Number of subjects: 28
Study 12162596 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium aspartate (2 vials K-Flebo d(‐1) = 60 mEq d(‐1), per os)
Number of subjects: 28
Study 12162596 — intervention group
Group type: COMPARATOR
Intervention: No potassium supplementation (control group)
Number of subjects: 28
Study 9710030 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (500 mg once a day for 5 days with a 10-day tapering period)
Number of subjects: 51
Study 9710030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 7802244 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-puncture technique (method A)
Number of subjects: 69
Study 7802244 — intervention group
Group type: COMPARATOR
Intervention: Catheter with a separate guide wire (method B)
Number of subjects: 69
Study 7802244 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter with an integral guide wire (method C)
Number of subjects: 69
Study 7802244 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter types B and C (polyurethane)
Number of subjects: 69
Study 2920502 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB 2086 (three times 40 mg/day) for 7 days
Number of subjects: 12
Study 2920502 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB 2086 (three times 100 mg/day) for 7 days
Number of subjects: 12
Study 2920502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 5732492 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 1
Study 5732492 — intervention group
Group type: COMPARATOR
Intervention: Ball-pulling (reinforcement schedule)
Number of subjects: 1
Study 5732492 — intervention group
Group type: COMPARATOR
Intervention: Free reinforcer delivery
Number of subjects: 1
Study 30169658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV) experienced in the past year
Number of subjects: 3496
Study 30169658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV) experienced as both a victim and perpetrator
Number of subjects: 3496
Study 28323838 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 150/300mg
Number of subjects: 40
Study 28323838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25186785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill count adherence
Number of subjects: 1219
Study 25186785 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 1219
Study 25186785 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable drug concentrations
Number of subjects: 1219
Study 24112970 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 292
Study 21133642 — intervention group
Group type: EXPERIMENTAL
Intervention: Total tonsillectomy
Number of subjects: 67
Study 21133642 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillotomy
Number of subjects: 67
Study 21133642 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched children)
Number of subjects: 67
Study 19482235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisone 25mg orally before stress test
Number of subjects: 50
Study 19482235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17376563 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation based teaching (SBT)
Number of subjects: 36
Study 17376563 — intervention group
Group type: COMPARATOR
Intervention: Lecture based teaching (LBT)
Number of subjects: 36
Study 17376563 — intervention group
Group type: COMPARATOR
Intervention: Combination of lecture and simulation (LAS)
Number of subjects: 36
Study 17376563 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT
Number of subjects: 36
Study 15538132 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 12
Study 15538132 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine (30 mg)
Number of subjects: 12
Study 15538132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11172153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral edema group
Number of subjects: 61
Study 11172153 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate treatment
Number of subjects: 61
Study 9550459 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasoenteral tube feedings at 125 cc/hour over 11 hours each night in addition to standard post-operative nutritional care
Number of subjects: 18
Study 9550459 — intervention group
Group type: COMPARATOR
Intervention: Standard post-operative care
Number of subjects: 18
Study 9550459 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasoenteral tube feedings
Number of subjects: 18
Study 7839535 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine treatment
Number of subjects: 289
Study 7839535 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 289
Study 2541121 — intervention group
Group type: EXPERIMENTAL
Intervention: WR-2721 and cis-platinum (150 mg/m2)
Number of subjects: 118
Study 2541121 — intervention group
Group type: EXPERIMENTAL
Intervention: WR-2721 and cis-platinum (120 mg/m2)
Number of subjects: 118
Study 2541121 — intervention group
Group type: EXPERIMENTAL
Intervention: WR-2721 and cis-platinum (cumulative dose of 725 mg/m2)
Number of subjects: 118
Study 2541121 — intervention group
Group type: EXPERIMENTAL
Intervention: WR-2721 and cis-platinum
Number of subjects: 118
Study 6402 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution 0.5%
Number of subjects: 0
Study 6402 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution 1.0%
Number of subjects: 0
Study 6402 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution 1.5%
Number of subjects: 0
Study 6402 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution (all concentrations)
Number of subjects: 0
Study 31175364 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori positive patients
Number of subjects: 250
Study 31175364 — intervention group
Group type: COMPARATOR
Intervention: Barrett's esophagus patients
Number of subjects: 250
Study 31175364 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of erosive esophagitis, length of BE, or dysplasia
Number of subjects: 250
Study 27659121 — intervention group
Group type: EXPERIMENTAL
Intervention: Version 1 of SBD measures
Number of subjects: 781
Study 27659121 — intervention group
Group type: EXPERIMENTAL
Intervention: Version 2 of SBD measures
Number of subjects: 781
Study 27659121 — intervention group
Group type: EXPERIMENTAL
Intervention: Version 3 of SBD measures
Number of subjects: 781
Study 27659121 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 5 (specific version of SBD measures)
Number of subjects: 781
Study 27659121 — intervention group
Group type: COMPARATOR
Intervention: All versions of SBD measures
Number of subjects: 781
Study 25962601 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) and adalimumab (DMARD+ADA)
Number of subjects: 150
Study 25962601 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) and placebo (DMARD+PLA)
Number of subjects: 150
Study 25962601 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of adalimumab (ADA) after 12 months of treatment
Number of subjects: 150
Study 25962601 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sCD163
Number of subjects: 150
Study 23782672 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression Medication Choice decision aid
Number of subjects: 300
Study 23782672 — intervention group
Group type: COMPARATOR
Intervention: Usual depression care
Number of subjects: 300
Study 21544671 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based survivorship care program
Number of subjects: 775
Study 19811180 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based learning (WBL)
Number of subjects: 148
Study 19811180 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face problem-based learning (PBL)
Number of subjects: 148
Study 17855815 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hemodynamic optimization strategies (early goal-directed therapy)
Number of subjects: 0
Study 17855815 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 14713799 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release ciprofloxacin 1,000 mg once daily
Number of subjects: 1035
Study 14713799 — intervention group
Group type: COMPARATOR
Intervention: Conventional ciprofloxacin 500 mg twice daily
Number of subjects: 1035
Study 10708840 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga (SKY)
Number of subjects: 45
Study 10708840 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 45
Study 10708840 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (IMN)
Number of subjects: 45
Study 8632216 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose vitamin A supplements
Number of subjects: 1407
Study 1575179 — intervention group
Group type: EXPERIMENTAL
Intervention: Duteplase (rt-PA) maintenance infusion at doses of 0.012, 0.024, 0.036, 0.048 MIU/kg/hour for 9 to 21 hours
Number of subjects: 213
Study 1575179 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dose of rt-PA administered
Number of subjects: 213
Study 1575179 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with serious bleeding
Number of subjects: 213
Study 6370150 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 250 mg daily
Number of subjects: 60
Study 6370150 — intervention group
Group type: COMPARATOR
Intervention: Dapsone 100 mg daily (50 mg/day for the first 7 days)
Number of subjects: 60
Study 31444929 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training (TreSPE) in addition to stretching and proprioceptive exercise
Number of subjects: 53
Study 31444929 — intervention group
Group type: COMPARATOR
Intervention: Stretching and proprioceptive exercise
Number of subjects: 53
Study 31126337 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 0
Study 31126337 — intervention group
Group type: COMPARATOR
Intervention: Psychological therapy
Number of subjects: 0
Study 31126337 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-7 questionnaire score of at least 10
Number of subjects: 0